Measles

One of the most contagious diseases known to humans. Before vaccination, nearly every child contracted measles.

9M+ Annual Cases (Pre-Vaccine)
2.6M Deaths Annually (Pre-Vaccine)
99% Vaccine Effectiveness (2 doses)

Disease Overview

What is Measles?

Measles is a highly contagious viral disease caused by the measles virus (a paramyxovirus). It spreads through airborne droplets and can remain infectious in the air for up to 2 hours.

  • Transmission: Airborne, highly contagious (R₀ ≈ 12-18)
  • Incubation: 10-14 days
  • Infectious Period: 4 days before to 4 days after rash
  • Case Fatality Ratio: 0.1-0.3% in developed countries; up to 5% in developing nations

Clinical Presentation

  1. 1 Fever, cough, coryza, conjunctivitis (3-5 days)
  2. 2 Koplik spots (white spots on buccal mucosa)
  3. 3 Characteristic rash (starts at hairline, spreads downward)
  4. 4 Complications: pneumonia, encephalitis, diarrhea

Pre-Vaccine Era: The Burden Before 1963

Before the introduction of the measles vaccine in 1963, measles was an almost universal childhood disease. Nearly 100% of children contracted measles by age 15.

3-4M

Annual reported cases in the U.S. (estimated actual: 4-5 million)

400-500

Annual deaths in the U.S. before vaccine introduction

48,000

Hospitalizations annually in the U.S. pre-vaccine

Global Impact (Pre-1980)

  • An estimated 2.6 million deaths annually globally from measles
  • In developing countries, measles case fatality rates reached 5-10% in malnourished populations
  • Measles was a leading cause of blindness in children due to vitamin A deficiency

Key Historical Context

The severity of measles was well-documented in medical literature. In the decade before the vaccine, measles was responsible for more deaths than all other vaccine-preventable diseases combined in the United States.

Vaccine Introduction & Measured Impact

Timeline: Measles Vaccination in the U.S.

1963 Licensing of Edmonston-B strain measles vaccine; initial coverage ~30%
1971 MMR (Measles, Mumps, Rubella) licensed, replacing single-antigen vaccines
1989 Second dose recommendation added (school entry requirement)
2000 Measles elimination declared in the U.S. (endemic transmission interrupted)

Vaccine Effectiveness

Dose Effectiveness
1 dose (at 12-15 months) 93%
2 doses (school age) 97%
Post-exposure prophylaxis ~90% if given within 72 hrs

Impact on Disease Burden

  • 99% reduction in U.S. cases vs. pre-vaccine era
  • 99% reduction in U.S. deaths vs. pre-vaccine era
  • 73% reduction in global measles deaths (2000-2018)
  • Regional elimination achieved in Americas, Western Pacific

Herd Immunity Threshold

Due to measles' high transmissibility (R₀ of 12-18), the herd immunity threshold is approximately 95% of the population must be immune to prevent sustained transmission.

Population immunity ≥95% Protects those who cannot be vaccinated Below threshold = outbreak risk

Current Situation & Surveillance

Global Progress Stalled

After decades of progress, global measles vaccination coverage has plateaued. The WHO reports that measles cases increased 79% globally in 2023-2024 compared to the previous year.

2023 Global Data

  • Reported cases worldwide>320,000
  • Estimated deaths~107,000
  • First-dose coverage83%
  • Second-dose coverage74%

U.S. Recent Outbreaks

  • 2024 cases (Jan-Nov)~280
  • Major outbreaksChicago, Texas, Pennsylvania
  • 2019 (pre-pandemic peak)1,274 cases
  • Most cases unvaccinated>90%

Risk Factors for Outbreaks

Low Vaccination Coverage

Communities below 95% threshold

International Travel

Unvaccinated travelers import cases

Under-12 Months

Too young for first dose

Available Vaccines

The measles vaccine is not available as a single-antigen vaccine in most countries. It is administered as combination vaccines:

MMR (Measles, Mumps, Rubella)

Routine

The most widely used measles-containing vaccine globally. Contains live attenuated viruses.

Schedule: 12-15 months (1st), 4-6 years (2nd)

Contraindications: Severe immunodeficiency, pregnancy, severe allergy

MMRV (Measles, Mumps, Rubella, Varicella)

Alternative

Combination vaccine for measles, mumps, rubella, and varicella (chickenpox).

Schedule: 12-23 months (single dose)

Note: Higher risk of febrile seizures vs. separate vaccines